

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

June 24, 2026

To whom it may concern:

TOWA PHARMACEUTICAL CO., LTD.

Notice of Changes in Officers

Towa Pharmaceutical Co., Ltd. (hereinafter, the “Company”) is pleased to announce the following changes in directors as resolved at its Ordinary General Meeting of Shareholders and Board of Directors meeting held on June 24, 2026.

1. New executive structure (As of June 24)
(Changes are underlined and bolded.)

	<u>New position</u>	Current position	Name
Reappointed	(Unchanged)	President and Representative Director	Itsuro Yoshida
Reappointed	<u>Senior Managing Director</u>	Executive Managing Director	Osamu Uchikawa
Reappointed	<u>Managing Director</u>	Director	Masaaki Takeyasu
Reappointed	(Unchanged)	Director	Toshikazu Kokubun
Newly appointed	<u>Director</u>	Operating Officer, General Manager of President’s Office and in charge of Corporate Strategy Division	Hideshi Nakamura
Reappointed	(Unchanged)	Outside Director	Norikazu Eiki*
Reappointed	(Unchanged)	Director (Full-time Audit and Supervisory Committee Member)	Masao Tanaka
Reappointed	(Unchanged)	Outside Director (Audit and Supervisory Committee Member)	Kaori Oishi*
—	(Unchanged)	Outside Director (Audit and Supervisory Committee Member)	Kenryo Goto*
Reappointed	(Unchanged)	Outside Director (Audit and Supervisory Committee Member)	Nobuki Ando*
Newly appointed	<u>Outside Director (Audit and Supervisory Committee Member)</u>	—	Muneya Taniguchi*

* Outside Directors as prescribed in Article 2, Item 15 of the Companies Act

Itsuro Yoshida, Osamu Uchikawa, Masaaki Takeyasu, Toshikazu Kokubun, and Hideshi

Nakamura are responsible officers under the revised Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

End of Notice